The new Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) HEDIS measure calculates the percentage of children ages 1–17 who have had two or more antipsychotic prescriptions filled and at least one metabolic test for blood glucose HbA1c, and at least one test for low-density lipoprotein cholesterol (LCL-C) or total cholesterol each year. Examples of first and second-generation antipsychotic medications included in this measure are chlorpromazine, aripiprazole, clozapine, olanzapine, risperidone, haloperidol, and trifluoperazine.
As you know, while antipsychotic medications are effective in treating certain mental illnesses in children, their side effects can lead to or exacerbate other health problems. Children taking antipsychotics are prone to significant weight gain and obesity-related complications such as cardiovascular issues, hypertension, hypercholesterolemia, and insulin-resistant type 2 diabetes. Consequently, it is important that patients on antipsychotic medication have annual metabolic testing.
In June, Harvard Pilgrim sent registries to pediatricians and prescribers, listing their patients ages 1-17 who had two or more antipsychotic prescriptions filled and were missing a cholesterol and/or blood glucose test in the calendar year. We will be sending these registries out twice a year, with the next mailing occurring in September. For more information about this Harvard Pilgrim initiative, contact the Clinical Programs Department at 800-287-9793 (option 1).